Commonwealth Equity Services LLC Sells 1,827 Shares of Takeda Pharmaceutical Company Limited (NYSE:TAK)

Commonwealth Equity Services LLC decreased its holdings in shares of Takeda Pharmaceutical Company Limited (NYSE:TAK) by 7.1% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 23,868 shares of the company’s stock after selling 1,827 shares during the quarter. Commonwealth Equity Services LLC’s holdings in Takeda Pharmaceutical were worth $309,000 at the end of the most recent quarter.

A number of other hedge funds also recently modified their holdings of TAK. Principal Securities Inc. acquired a new position in shares of Takeda Pharmaceutical in the 4th quarter worth approximately $28,000. Wells Fargo & Company MN increased its stake in shares of Takeda Pharmaceutical by 1.7% in the 4th quarter. Wells Fargo & Company MN now owns 774,552 shares of the company’s stock valued at $11,053,000 after buying an additional 12,756 shares during the period. Aigen Investment Management LP bought a new position in shares of Takeda Pharmaceutical in the 4th quarter worth $197,000. Catalytic Wealth RIA LLC bought a new position in shares of Takeda Pharmaceutical in the 4th quarter worth $233,000. Finally, Gold Investment Management Ltd. bought a new position in shares of Takeda Pharmaceutical in the 4th quarter worth $994,000. Institutional investors own 9.17% of the company’s stock.

Takeda Pharmaceutical Stock Performance

TAK stock opened at $14.91 on Tuesday. The business’s 50-day moving average price is $14.35 and its two-hundred day moving average price is $13.75. The company has a current ratio of 1.26, a quick ratio of 0.74 and a debt-to-equity ratio of 0.65. The firm has a market cap of $47.19 billion, a PE ratio of 27.11, a P/E/G ratio of 0.27 and a beta of 0.54. Takeda Pharmaceutical Company Limited has a 1-year low of $12.57 and a 1-year high of $16.06.

Takeda Pharmaceutical (NYSE:TAK) last issued its quarterly earnings results on Wednesday, July 31st. The company reported $0.56 EPS for the quarter, beating analysts’ consensus estimates of $0.37 by $0.19. The company had revenue of $7.75 billion for the quarter. Takeda Pharmaceutical had a return on equity of 10.11% and a net margin of 6.02%. As a group, research analysts forecast that Takeda Pharmaceutical Company Limited will post 1.63 earnings per share for the current year.

Takeda Pharmaceutical Profile

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.